Fig. 1: Clinical outcomes of AML patients with IDH2 mutations at baseline and the association with MRD after allogeneic hematopoietic cell transplant.
From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Cumulative incidence of relapse (left) and overall survival (right) are shown for IDH2 mutated patients (a) for the entire cohort (b) based on the presence (Flow MRDpos) or absence (Flow MRDneg) of reported clinical flow cytometry measurable residual disease (MRD), and (c) based on the presence (IDH2 NGS MRDpos) or absence (IDH2 NGS MRD neg) of residual IDH2 variants by next generation sequencing (NGS) MRD assay.
